Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 46

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 46
---
 any new treatments
that enter the market. We believe that a significant number of products are currently under development, and may become commercially
available in the future, for the treatment of conditions for which we may try to develop product candidates.

Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we have. If we obtain approval for any product candidate, we will face competition based on many different factors, including the
quality and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept
relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of
manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present
superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than
any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense
of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact
our level of expertise and our ability to execute our business plan.

Any
inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.

Our
success largely depends on the continued service of certain key management and other specialized personnel, including Anatoly Dritschilo,
M.D., our Chief Executive Officer, Timothy Lorber, our Chief Financial Officer, Mira Jung, Ph.D., our Chief Scientific Officer, Michael
Vander Hoek, our Vice President Operations and Regulatory, and Peter Dritschilo, our President and Chief Operating Officer. The loss
of one or more members of our management team or other key employees or advisors could delay our research and development programs and
materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have
cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued
service of our technical personnel because of the highly technical nature of our product candidates and technologies and the specialized
nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued
service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies
on any of our management team members or key employees. Our future success will